GLP-1

GLP-1 weight loss plateaus are driven by metabolic adaptation and lean mass loss — here's the evidence-based strategy…

GLP-1 medications can drive 15–24% weight loss, but clinical data reveals significant lean mass losses — here's what…

Emerging research published in JAMA Neurology, JAMA Psychiatry, and Alzheimer's Research & Therapy reveals that GLP-1 receptor agonists…

Injecting Ozempic into muscle instead of subcutaneous fat alters the drug's absorption rate and increases the risk of…

GLP-1 supplements claim to mimic the appetite-suppressing effects of semaglutide and tirzepatide, but here's what the actual research…

A 2025 meta-analysis reveals that roughly 25% of weight lost on semaglutide and tirzepatide comes from lean mass…

Up to 45% of weight lost on semaglutide may come from skeletal muscle — here's what the latest…

Ozempic is FDA-approved for diabetes, but the clinical evidence for weight loss in non-diabetic men is compelling —…

Emerging research reveals a direct connection between GLP-1 gut hormones, peripheral serotonin signaling, and cardiovascular health — and…

Clinical data shows semaglutide users can expect noticeable appetite changes within weeks and up to 11–12 kg of…